Kinase Chemistry – Just a year and a half behind the times.

Archive for the ‘Pharmacopeia’ Category

Ceph ‘n’ PCOP got C-Met

Posted by kinasepro on August 21, 2008

The 15M Pharmacopeia and Cephalon deal from a couple years ago was likely for compounds like these c-Met / Alk inhibitors:




yeh, its 1300 pages and I know they’re old, but I got some catching up to do…

Posted in c-Met, Cephalon, Pharmacopeia | Leave a Comment »

Schering’s latest CDK stuff

Posted by kinasepro on March 27, 2007

Schering-Plough has a series of CDK inhibitors of which the latest installment is: US20070066621. Earlier app’s in this series appear as a combined effort via SP and PCOP, and Pharmacopeia has a press release suggesting that the collaboration has an oncology candidate in Ph1. Hrmph, No ph1 oncology trials via ScheringP in the US and the press on this stuff is a little thin.


Vernalis described related series’ in Bioorg Med Chem Lett ’05, 863; 1Y8Y 1Y91 and Bioorg Med Chem Lett ’06, 1353; 2C68, 2C69, 2C6T, 2C6O, 2C6M, 2C6L, 2C6K, 2C6I

Posted in CDK2, Pharmacopeia, Schering-Plough | Leave a Comment »

Wyeth gets Jak’d up!

Posted by kinasepro on December 30, 2006

via Jak3 but of course – in an underanounced deal with Pharmacopeia:

…Wyeth will pay Pharmacopeia $5 million initially, as much as $9 million of research funding over the next three years, and as much as $175 million for reaching certain goals with the JAK3 kinase inhibitor drug.

While it’s likely they have a few which haven’t published yet, WO/2006/108103 is the most recent PCOP Jak3 application.


They’ve been at this stuff for a while – I reckon since WO/2001/047921 and have a recent Tet Lett on a related series. Check 2HK5 for a clue on how they bind.

>> update 1/25/07 >> US20070021443 Jak3 Pharmacopeia patent application

Posted in Deals, JAK, Pharmacopeia, Wyeth | 3 Comments »